title: Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages.
abstract: OBJECTIVE
  Atherosclerosis plaque development includes infiltration of inflammatory cells, accumulation of lipids and fibrous cap formation. Low-density lipoprotein receptor-related protein 1 (LRP1) is expressed on atherosclerotic lesions associated with macrophages and vascular smooth muscle cells. The aim of this work is to analyse the role in atherosclerosis lesion progression of another member of the LDL receptor protein family, low-density lipoprotein receptor-related protein 5 (LRP5), a co-receptor with Frizzled known to activate the Wnt signalling pathway in several cell types.
  
  
  RESULTS
  LRP5 is expressed in human vascular and innate inflammatory cells. LRP5 is transcriptionally regulated by aggregated LDL (agLDL), participating in the lipid uptake and transformation of macrophages into foam cells, a critical step in atherosclerosis progression. AgLDL-treated macrophages show up-regulated expression of β-catenin, LEF1, c-jun, cyclinD1, bone morphogenetic protein 2 (BMP2), and osteopontin (OPN), proteins and targets of the Wnt signalling pathway, whereas LRP5-silenced macrophages show a significant down-regulation of OPN and BMP2 expression. Furthermore, LRP5-deficient macrophages exhibit an impaired migration both in wound-repair and modified Boyden chambers models.
  
  
  CONCLUSIONS
  These results demonstrate the involvement of LRP5 in the innate inflammatory reaction to lipid infiltration in atherosclerosis.
authors.affiliation: Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau, UAB, Barcelona, Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: Borrell-Pagès
authors.forename: July Carolina
authors.initials: JC
authors.lastname: Romero
authors.forename: Oriol
authors.initials: O
authors.lastname: Juan-Babot
authors.forename: Lina
authors.initials: L
authors.lastname: Badimon
mesh_terms: D017209:Apoptosis / Q000502:physiology; D050197:Atherosclerosis / Q000209:etiology* / Q000378:metabolism; D055396:Bone Morphogenetic Protein 2 / Q000378:metabolism; D002454:Cell Differentiation / Q000502:physiology; D002465:Cell Movement / Q000502:physiology*; D002470:Cell Survival / Q000502:physiology; D002478:Cells, Cultured; D005487:Foam Cells / Q000502:physiology; D006801:Humans; D050356:Lipid Metabolism / Q000502:physiology*; D008077:Lipoproteins, LDL / Q000494:pharmacology; D060492:Low Density Lipoprotein Receptor-Related Protein-5 / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D008264:Macrophages / Q000378:metabolism*; D009000:Monocytes / Q000378:metabolism; D053495:Osteopontin / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D060449:Wnt Signaling Pathway / Q000502:physiology*
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D008077:Lipoproteins, LDL; D060492:Low Density Lipoprotein Receptor-Related Protein-5; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D053495:Osteopontin